United States Biotechnology & Medical Research

Eledon Pharmaceuticals Inc (ELDN)

Track

Eledon Pharmaceuticals Inc. has recorded no insider trading activity within the last 90 days. The most recent transactions occurred on May 5, 2023, involving significant share acquisitions by BVF Partners L.P. Prior to this, various executives and institutional holders engaged in buying and selling activity, with the last recorded transaction dating back over three years.
Ticker: ELDN Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Eledon Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
4.0
BVF PARTNERS L P/IL Large shareholder
Transaction date
Purchase
Price
34.15
Quantity 75,799
Value US$4,217,410
4.0
BVF PARTNERS L P/IL Large shareholder
Transaction date
Purchase
Price
432.71
Quantity 95,567
Value US$4,019,283
4.0
BVF PARTNERS L P/IL Large shareholder
Transaction date
Purchase
Price
261.41
Quantity 97,162
Value US$222,228
1.0
Perrin Steven President Executive Director
Transaction date
Purchase
Price
2.60
Quantity 1,000 +inf%
Value US$2,597
1.2
Gros David-Alexandre C Chief Executive Officer Executive Director
Transaction date
Purchase
Price
4.48
Quantity 2,000 +28.6%
Value US$8,960
0.7
Little Paul Sean CHIEF FINANCIAL OFFICER Officer
Transaction date
Purchase
Price
8.87
Quantity 10,000 +inf%
Value US$88,700
1.2
Gros David-Alexandre C Chief Executive Officer Executive Director
Transaction date
Purchase
Price
8.01
Quantity 3,000 +inf%
Value US$24,030
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Sale
Price
21.60
Quantity 103,200 -58.4%
Value US$2,229,120
3.6
FLESHER GREGORY J. Chief Executive Officer
Transaction date
Sale
Price
1.91
Quantity 2,937 -1.8%
Value US$5,614
3.6
Kuwahara Jon See Remarks
Transaction date
Sale
Price
1.91
Quantity 1,058 -15.0%
Value US$2,022
3.6
TURKEL CATHERINE C. President
Transaction date
Sale
Price
1.91
Quantity 1,914 -2.1%
Value US$3,658
3.6
FLESHER GREGORY J. Chief Executive Officer
Transaction date
Sale
Price
1.96
Quantity 11,701 -6.8%
Value US$22,953
3.6
Kuwahara Jon See Remarks
Transaction date
Sale
Price
1.96
Quantity 4,218 -37.5%
Value US$8,274
3.6
TURKEL CATHERINE C. President
Transaction date
Sale
Price
1.96
Quantity 7,623 -7.8%
Value US$14,953
Chimovits Erez
Transaction date
Purchase
Price
3.10
Quantity 646,204 +25.5%
Value US$2,003,232
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Purchase
Price
3.10
Quantity 646,204 +25.5%
Value US$2,003,232
TURKEL CATHERINE C. President Officer
Transaction date
Purchase
Price
5.02
Quantity 16,632 +27.0%
Value US$83,476
TURKEL CATHERINE C. President Officer
Transaction date
Purchase
Price
4.56
Quantity 17,048 +38.3%
Value US$77,671
TURKEL CATHERINE C. President Officer
Transaction date
Purchase
Price
3.97
Quantity 805 +inf%
Value US$3,193
FLESHER GREGORY J. Chief Executive Officer Executive Director
Transaction date
Purchase
Price
9.99
Quantity 58,959 +103.6%
Value US$589,000
TURKEL CATHERINE C. Chief Development Officer Officer
Transaction date
Purchase
Price
9.99
Quantity 11,111 +82.9%
Value US$110,999
OCAMPO CHRISTINE See Remarks Officer
Transaction date
Purchase
Price
9.99
Quantity 10,010 +86.4%
Value US$100,000
Buckley Stephen Jr. Non-Executive Director
Transaction date
Purchase
Price
5.74
Quantity 8,000 +266.7%
Value US$45,920
Buckley Stephen Jr. Non-Executive Director
Transaction date
Purchase
Price
11.25
Quantity 3,000 +inf%
Value US$33,750
McBride John S. Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.01
Quantity 13,500 -100.0%
Value US$189,135
Morrison Jodie Pope President and CEO Executive Director
Transaction date
Planned sale
Price
13.70
Quantity 564 -2.8%
Value US$7,727
Morrison Jodie Pope President and CEO Executive Director
Transaction date
Planned sale
Price
13.70
Quantity 12,000 -38.0%
Value US$164,400
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.26
Quantity 3,566 -0.1%
Value US$50,844
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.41
Quantity 27,861 -0.6%
Value US$401,477
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.20
Quantity 20,611 -0.5%
Value US$292,717
Morrison Jodie Pope President and CEO Executive Director
Transaction date
Planned sale
Price
13.70
Quantity 8,000 -45.6%
Value US$109,600
Morrison Jodie Pope President and CEO Executive Director
Transaction date
Planned sale
Price
13.83
Quantity 8,000 -45.6%
Value US$110,640
McBride John S. Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.20
Quantity 300 -100.0%
Value US$4,260
McBride John S. Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.00
Quantity 6,700 -100.0%
Value US$93,800
McBride John S. Chief Operating Officer Officer
Transaction date
Planned sale
Price
14.02
Quantity 2,000 -100.0%
Value US$28,040
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.27
Quantity 1,120 -0.0%
Value US$15,982
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.20
Quantity 5,919 -0.1%
Value US$84,050
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.20
Quantity 27,875 -0.6%
Value US$395,825
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.50
Quantity 46,141 -1.0%
Value US$669,044
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.50
Quantity 3,000 -0.1%
Value US$43,500
Apple Tree Partners II - Annex, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 237,500 +7.1%
Value US$3,562,500
Novartis Bioventures Ltd Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 325,000 +7.5%
Value US$4,875,000
Harrison Seth Loring Non-Executive Director Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 362,500 +4.8%
Value US$5,437,500
Satter Muneer A Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 150,000 +9.2%
Value US$2,250,000
Novartis Bioventures Ltd Large shareholder
Transaction date
Sale
Price
14.20
Quantity 14,777 -0.3%
Value US$209,833
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-05-09 2023-05-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
75,799
34.15
US$4,217,410 		75,799 34.15 US$4,217,410
2023-05-09 2023-05-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
95,567
432.71
US$4,019,283 		95,567 432.71 US$4,019,283
2023-05-09 2023-05-05 B Purchase
4.0
BVF PARTNERS L P/IL
Large shareholder
97,162
261.41
US$222,228 		97,162 261.41 US$222,228
2022-11-23 2022-11-23 B Purchase
1.0
Perrin Steven

President

Executive Director
1,000 +inf%
2.60
US$2,597 		1,000 +inf% 2.60 US$2,597
2021-12-21 2021-12-20 B Purchase
1.2
Gros David-Alexandre C

Chief Executive Officer

Executive Director
2,000 +28.6%
4.48
US$8,960 		2,000 +28.6% 4.48 US$8,960
2021-06-14 2021-06-11 B Purchase
0.7
Little Paul Sean

CHIEF FINANCIAL OFFICER

Officer
10,000 +inf%
8.87
US$88,700 		10,000 +inf% 8.87 US$88,700
2021-06-10 2021-06-09 B Purchase
1.2
Gros David-Alexandre C

Chief Executive Officer

Executive Director
3,000 +inf%
8.01
US$24,030 		3,000 +inf% 8.01 US$24,030
2020-12-04 2020-12-02 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
103,200 -58.4%
21.60
US$2,229,120 		103,200 -58.4% 21.60 US$2,229,120
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
9,098 +4.2%
25.55
US$232,460 		9,098 +4.2% 25.55 US$232,460
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
15,000 +7.5%
26.17
US$392,610 		15,000 +7.5% 26.17 US$392,610
2020-11-06 2020-10-30 S Sale
1.0
Logos Global Management LP
Large shareholder
27 -0.0%
27.02
US$730 		27 -0.0% 27.02 US$730
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
12,942 +6.9%
25.88
US$334,926 		12,942 +6.9% 25.88 US$334,926
2020-11-06 2020-10-30 S Sale
1.0
Logos Global Management LP
Large shareholder
12,942 -6.5%
26.64
US$344,829 		12,942 -6.5% 26.64 US$344,829
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
15,000 +8.1%
26.48
US$397,236 		15,000 +8.1% 26.48 US$397,236
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
4,000 +2.2%
25.97
US$103,892 		4,000 +2.2% 25.97 US$103,892
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
31,000 +20.7%
24.53
US$760,427 		31,000 +20.7% 24.53 US$760,427
2020-11-06 2020-10-30 B Purchase
1.0
Logos Global Management LP
Large shareholder
5,000 +3.4%
24.03
US$120,162 		5,000 +3.4% 24.03 US$120,162
2019-05-22 2019-05-21 S Sale
3.6
FLESHER GREGORY J.

Chief Executive Officer
2,937 -1.8%
1.91
US$5,614 		2,937 -1.8% 1.91 US$5,614
2019-05-22 2019-05-21 S Sale
3.6
Kuwahara Jon

See Remarks
1,058 -15.0%
1.91
US$2,022 		1,058 -15.0% 1.91 US$2,022
2019-05-22 2019-05-21 S Sale
3.6
TURKEL CATHERINE C.

President
1,914 -2.1%
1.91
US$3,658 		1,914 -2.1% 1.91 US$3,658
2019-05-22 2019-05-20 S Sale
3.6
FLESHER GREGORY J.

Chief Executive Officer
11,701 -6.8%
1.96
US$22,953 		11,701 -6.8% 1.96 US$22,953
2019-05-22 2019-05-20 S Sale
3.6
Kuwahara Jon

See Remarks
4,218 -37.5%
1.96
US$8,274 		4,218 -37.5% 1.96 US$8,274
2019-05-22 2019-05-20 S Sale
3.6
TURKEL CATHERINE C.

President
7,623 -7.8%
1.96
US$14,953 		7,623 -7.8% 1.96 US$14,953
2019-05-06 2019-05-02 B Purchase
Chimovits Erez
646,204 +25.5%
3.10
US$2,003,232 		646,204 +25.5% 3.10 US$2,003,232
2019-05-06 2019-05-02 B Purchase
3.9
OrbiMed Israel GP Ltd.
Large shareholder
646,204 +25.5%
3.10
US$2,003,232 		646,204 +25.5% 3.10 US$2,003,232
2019-05-02 2019-04-30 S Sale
3.3
LIFESCI INDEX PARTNERS LLC
Large shareholder
200 -0.0%
2.70
US$540 		200 -0.0% 2.70 US$540
2018-09-13 2018-09-12 B Purchase TURKEL CATHERINE C.

President

Officer
16,632 +27.0%
5.02
US$83,476 		16,632 +27.0% 5.02 US$83,476
2018-09-13 2018-09-11 B Purchase TURKEL CATHERINE C.

President

Officer
17,048 +38.3%
4.56
US$77,671 		17,048 +38.3% 4.56 US$77,671
2018-09-07 2018-09-05 B Purchase TURKEL CATHERINE C.

President

Officer
805 +inf%
3.97
US$3,193 		805 +inf% 3.97 US$3,193
2017-05-11 2017-05-10 B Purchase FLESHER GREGORY J.

Chief Executive Officer

Executive Director
58,959 +103.6%
9.99
US$589,000 		58,959 +103.6% 9.99 US$589,000
2017-05-11 2017-05-10 B Purchase TURKEL CATHERINE C.

Chief Development Officer

Officer
11,111 +82.9%
9.99
US$110,999 		11,111 +82.9% 9.99 US$110,999
2017-05-11 2017-05-10 B Purchase OCAMPO CHRISTINE

See Remarks

Officer
10,010 +86.4%
9.99
US$100,000 		10,010 +86.4% 9.99 US$100,000
2016-03-15 2016-03-15 B Purchase Buckley Stephen Jr. Non-Executive Director
8,000 +266.7%
5.74
US$45,920 		8,000 +266.7% 5.74 US$45,920
2015-11-12 2015-11-11 B Purchase Buckley Stephen Jr. Non-Executive Director
3,000 +inf%
11.25
US$33,750 		3,000 +inf% 11.25 US$33,750
2015-09-22 2015-09-21 PlS Planned sale McBride John S.

Chief Operating Officer

Officer
13,500 -100.0%
14.01
US$189,135 		13,500 -100.0% 14.01 US$189,135
2015-07-30 2015-07-29 PlS Planned sale Morrison Jodie Pope

President and CEO

Executive Director
564 -2.8%
13.70
US$7,727 		564 -2.8% 13.70 US$7,727
2015-07-30 2015-07-28 PlS Planned sale Morrison Jodie Pope

President and CEO

Executive Director
12,000 -38.0%
13.70
US$164,400 		12,000 -38.0% 13.70 US$164,400
2015-07-17 2015-07-15 S Sale Novartis Bioventures Ltd Large shareholder
3,566 -0.1%
14.26
US$50,844 		3,566 -0.1% 14.26 US$50,844
2015-07-15 2015-07-14 S Sale Novartis Bioventures Ltd Large shareholder
27,861 -0.6%
14.41
US$401,477 		27,861 -0.6% 14.41 US$401,477
2015-07-15 2015-07-13 S Sale Novartis Bioventures Ltd Large shareholder
20,611 -0.5%
14.20
US$292,717 		20,611 -0.5% 14.20 US$292,717
2015-06-30 2015-06-29 PlS Planned sale Morrison Jodie Pope

President and CEO

Executive Director
8,000 -45.6%
13.70
US$109,600 		8,000 -45.6% 13.70 US$109,600
2015-06-30 2015-06-26 PlS Planned sale Morrison Jodie Pope

President and CEO

Executive Director
8,000 -45.6%
13.83
US$110,640 		8,000 -45.6% 13.83 US$110,640
2015-06-24 2015-06-24 PlS Planned sale McBride John S.

Chief Operating Officer

Officer
300 -100.0%
14.20
US$4,260 		300 -100.0% 14.20 US$4,260
2015-06-24 2015-06-23 PlS Planned sale McBride John S.

Chief Operating Officer

Officer
6,700 -100.0%
14.00
US$93,800 		6,700 -100.0% 14.00 US$93,800
2015-06-24 2015-06-22 PlS Planned sale McBride John S.

Chief Operating Officer

Officer
2,000 -100.0%
14.02
US$28,040 		2,000 -100.0% 14.02 US$28,040
2015-06-18 2015-06-16 S Sale Novartis Bioventures Ltd Large shareholder
1,120 -0.0%
14.27
US$15,982 		1,120 -0.0% 14.27 US$15,982
2015-06-16 2015-06-12 S Sale Novartis Bioventures Ltd Large shareholder
5,919 -0.1%
14.20
US$84,050 		5,919 -0.1% 14.20 US$84,050
2015-06-12 2015-06-11 S Sale Novartis Bioventures Ltd Large shareholder
27,875 -0.6%
14.20
US$395,825 		27,875 -0.6% 14.20 US$395,825
2015-03-20 2015-03-19 S Sale Novartis Bioventures Ltd Large shareholder
46,141 -1.0%
14.50
US$669,044 		46,141 -1.0% 14.50 US$669,044
2015-03-20 2015-03-18 S Sale Novartis Bioventures Ltd Large shareholder
3,000 -0.1%
14.50
US$43,500 		3,000 -0.1% 14.50 US$43,500
2014-09-24 2014-09-22 B Purchase Apple Tree Partners II - Annex, L.P. Non-Executive Director Large shareholder
237,500 +7.1%
15.00
US$3,562,500 		237,500 +7.1% 15.00 US$3,562,500
2014-09-24 2014-09-22 B Purchase Novartis Bioventures Ltd Large shareholder
325,000 +7.5%
15.00
US$4,875,000 		325,000 +7.5% 15.00 US$4,875,000
2014-09-24 2014-09-22 B Purchase Harrison Seth Loring Non-Executive Director Large shareholder
362,500 +4.8%
15.00
US$5,437,500 		362,500 +4.8% 15.00 US$5,437,500
2014-09-24 2014-09-22 B Purchase Satter Muneer A Large shareholder
150,000 +9.2%
15.00
US$2,250,000 		150,000 +9.2% 15.00 US$2,250,000
2015-06-16 2014-06-15 S Sale Novartis Bioventures Ltd Large shareholder
14,777 -0.3%
14.20
US$209,833 		14,777 -0.3% 14.20 US$209,833
Explore more

More insider trading research around Eledon Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America